Literature DB >> 31062086

IL-33 in the tumor microenvironment is associated with the accumulation of FoxP3-positive regulatory T cells in human esophageal carcinomas.

Guanglin Cui1,2, Zhenfeng Li3, Jingli Ren4, Aping Yuan3,5.   

Abstract

Forkhead box p3 (Foxp3+) regulatory T cells (Tregs) are abundant in the tumor microenvironment where they dampen functions of host anti-tumor immunity and promote cancer progression. Cytokine signaling is essential for the generation and function maintenance of Tregs in patients with cancers. Recent in vitro and in vivo studies have described that interleukin (IL)-33 plays a critical role in regulating the expansion and function of Tregs. However, the regulatory role of IL-33 in Treg recruitment within the microenvironment of human esophageal squamous cell carcinoma (ESCC) to date is poorly understood. In this study, we have therefore characterized the expression of IL-33 by immunohistochemistry (IHC) and double immunofluorescence staining and analyzed its relationship with FoxP3+ Treg accumulation in the microenvironment in 80 patients with ESCC. IHC observation revealed a high expression level of IL-33 in both ESCC mass and stroma, which paralleled to a high density of FoxP3+ Tregs accumulated in the same compartments. Statistical analysis showed that the scores for cell densities of tumor- and stroma-expressing IL-33 were significantly correlated with the scores for density of FoxP3+ Tregs in the tumor stroma. Further immunofluorescence images demonstrated that IL-33 functional receptor, ST2, was preferentially expressed in FoxP3+ Tregs, suggesting a possible effecting pathway for IL-33. In addition, cyclooxygenase-2, one of the important immunosuppressive factors, was highly illustrated in FoxP3+ Tregs. We have therefore concluded that microenvironmental-expressing IL-33 is associated with the recruitment of Tregs in human ESCCs.

Entities:  

Keywords:  Esophageal carcinoma; Interleukin-33; Microenvironment; Regulatory T cells; ST2

Mesh:

Substances:

Year:  2019        PMID: 31062086     DOI: 10.1007/s00428-019-02579-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  40 in total

Review 1.  Changes of immunocytic phenotypes and functions from human colorectal adenomatous stage to cancerous stage: Update.

Authors:  Yanhong Shi; Zhenfeng Li; Wei Zheng; Xia Liu; Chenyi Sun; Jann-Birger Laugsand; Zhanju Liu; Guanglin Cui
Journal:  Immunobiology       Date:  2015-06-17       Impact factor: 3.144

2.  The Global Burden of Cancer 2013.

Authors:  Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

3.  FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism.

Authors:  Milada Mahic; Sheraz Yaqub; C Christian Johansson; Kjetil Taskén; Einar M Aandahl
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

4.  Cellular changes in the tumor microenvironment of human esophageal squamous cell carcinomas.

Authors:  Jinzhong Liu; Zhenfeng Li; Jing Cui; Gang Xu; Guanglin Cui
Journal:  Tumour Biol       Date:  2011-12-02

Review 5.  Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications.

Authors:  S Strand; P R Galle
Journal:  Mol Med Today       Date:  1998-02

6.  Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.

Authors:  Martina Mandarano; Guido Bellezza; Maria Laura Belladonna; Benoit J Van den Eynde; Rita Chiari; Jacopo Vannucci; Giada Mondanelli; Vienna Ludovini; Ivana Ferri; Fortunato Bianconi; Rachele Del Sordo; Lucio Cagini; Elisa Albini; Giulio Metro; Francesco Puma; Angelo Sidoni
Journal:  Virchows Arch       Date:  2018-11-17       Impact factor: 4.064

7.  IL-33 induces both regulatory B cells and regulatory T cells in dextran sulfate sodium-induced colitis.

Authors:  Junfeng Zhu; Ying Xu; Chunyu Zhu; Jian Zhao; Xinrui Meng; Siyao Chen; Tianqi Wang; Xue Li; Li Zhang; Changlong Lu; Hongsheng Liu; Xun Sun
Journal:  Int Immunopharmacol       Date:  2017-02-28       Impact factor: 4.932

8.  High intratumoural but not peritumoural inflammatory host response is associated with better prognosis in primary resected oesophageal adenocarcinomas.

Authors:  Alexandra V Stein; Bastian Dislich; Annika Blank; Lars Guldener; Dino Kröll; Christian A Seiler; Rupert Langer
Journal:  Pathology       Date:  2016-12-02       Impact factor: 5.306

9.  Increased expression of interleukin-21 along colorectal adenoma-carcinoma sequence and its predicating significance in patients with sporadic colorectal cancer.

Authors:  Guanglin Cui; Aping Yuan; Li Zhu; Jon Florholmen; Rasmus Goll
Journal:  Clin Immunol       Date:  2017-09-05       Impact factor: 3.969

Review 10.  The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases.

Authors:  Brad Griesenauer; Sophie Paczesny
Journal:  Front Immunol       Date:  2017-04-24       Impact factor: 7.561

View more
  3 in total

1.  Oesophageal squamous cell carcinoma-associated IL-33 rewires macrophage polarization towards M2 via activating ornithine decarboxylase.

Authors:  Shijie Mai; Le Liu; Jianjun Jiang; Pengfei Ren; Dingwei Diao; Haofei Wang; Kaican Cai
Journal:  Cell Prolif       Date:  2020-12-10       Impact factor: 6.831

Review 2.  The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma.

Authors:  Shuyue Zheng; Beilei Liu; Xinyuan Guan
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

3.  ST2 and regulatory T cells in the colorectal adenoma/carcinoma microenvironment: implications for diseases progression and prognosis.

Authors:  Guanglin Cui; Aping Yuan; Zhenfeng Li; Rasmus Goll; Jon Florholmen
Journal:  Sci Rep       Date:  2020-04-03       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.